Why should companies come to CBI for ocular preclinical
studies? Because we simply are the best. We are a smaller
company, owned and operated by scientists with a lifetime
of experience in drug discovery and development. Our
study directors are graduates of top academic institutions
and bring all their skills to each of our studies. We feature
a scientific and not so much a bean-counting mind set
towards our studies. Most of us have direct experience with
successful IND submissions and have many scientific peer
reviewed publications.
This year, we added OCT to our ocular capabilities. We
partnered with Bioptigen and purchased the Bioptigen
Envisu R-Class system. This system is designed to provide
the best in high throughput, high resolution imaging and is
suitable for rapid screening and in-depth analysis with
unparalleled imaged quality and maximum flexibility.
Optical Coherence Tomography (OCT) offers some terrific
technological advances that allow a refined cross-sectional
view of the retina, the retinal-vitreal interface, and anterior
ocular structures at near-cellular resolution. In the clinic it is
used to diagnose and follow ocular degenerative diseases.
